Fig. 4
From: The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment
Comparison of In Vivo Antitumor Activity of VHH CD70 CAR-T. 11C9 CAR-T cells showed highest eradication potency against tumor cell. A Schematic representation of the ACHN xenograft RCC model in NOG mice. These mice were inoculated with 5 × 106 ACHN cells subcutaneously and received 2 dosages of CAR-T cells (1 × 106 or 5 × 106 CAR + cells/mouse) intravenously. All mice in the 5 × 106 CAR + dose CAR-T treated groups (2A5-H,11C-H,41D12-H) and 11C9 1 × 106 CAR + treated groups (11C9-L) were re-challenged on day 63 with 5 × 106 ACHN cells. B Tumor growth curves after the first tumor injection in all mice treated with CD70 CAR-T, non-transduced (NT), or vehicle control (Cell Cryopreservation Solution). C Tumor growth curves after re-challenge. Only 11C9-H mice showed robust tumor growth inhibition. D Human T cell counts in peripheral blood of mice measured by flow cytometry. ***P < 0.001, ****P < 0.0001 by Student’s t test. E The concentration of human IFN-γ and IL-6 in peripheral blood of mice at day7 and day 14 after T cell infusion were analyzed by CBA. *P < 0.05,**P < 0.01, *** P < 0.001 by Student’s t test